Fig. 4: Probability that the IXCHIQ vaccine benefits outweigh the risks of vaccine SAEs and deaths by age group and epidemiological scenario, assuming a vaccine efficacy of 95%.
From: A framework for risk–benefit analysis of vaccines approved through accelerated pathways
Open diamonds show the evidence available at the end of the trial, and filled circles show all evidence currently available. Vertical dashed lines denote 95% probability (n = 100,000 posterior samples).
